Study Details

Open

PRevention Of Frailty with Fisetin (PROFFi) in Breast Cancer Survivors

The purpose of this research study is to examine the effectiveness of the nutritional supplement, fisetin, in improving physical function in women treated for breast cancer.

Age & Gender

18 years ~ 70 years
Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)
Visits can be combined with regular clinical appointments

Location

United States (Nationwide)

What will be asked of you

Your medical history, performance status, blood tests will be assessed and reviewed. you will be asked to do a 6 minute walk distance. oral drugs will be given if eligible. clinical exams will be performed, telehealth exercise program will be assessed and physical function tests will be done. you will also be asked to complete health questionnaires.

Incentives

$25 gift cards paid out twice

Total length of participation:
78 months

Looking for Specific Volunteers

Able to participate:

You are a postmenopausal female at the start of study treatment
You have been diagnosed with early-stage breast cancer (Stage I, II, III) and were treated with neo-adjuvant chemotherapy within 12 months of starting study treatment.
You have no evidence of active or recurrent breast cancer.
You have evidence of pre-frail health, defined as a 6-minute walk distance at baseline (400-480m)

Not eligible if:

You have received treatment for cancer within 30 days prior to the start of study treatment. Exceptions include: trastuzumab, pertuzumab, pembrolizumab, tamoxifen, and aromatase inhibitors
You have had surgery and/or radiation within the last 30 days of starting study treatment
You are taking herbal and natural medications with possible senolytic properties (i.e., curcumin, kava kava, St. John's wort) and are unable or unwilling to hold
You are taking therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.)
You are unable to tolerate oral medications

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

Lineberger Comprehensive Cancer Center
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Hyman Muss
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)

IRB Number

23-2199

ClinicalTrials.gov

NCT06113016